Autres langues Gedeon Richter LUXEMBOURG S.E.

Actions

CHWGR

US3684672054

Produits pharmaceutiques

Cours en clôture LUXEMBOURG S.E. Autres places de cotation 31/07/2026			Varia. 5j.	Varia. 1 janv.
37,40 ^USD	-.--%		+1,63 %	+23,84 %

29/06	Gedeon Richter Plc. annonce la démission de Péter Cserháti de son poste de membre du conseil d'administration, avec effet au 1er juillet 2026	CI
16/06	L'IA en Hongrie pourrait générer 15 milliards d'euros de gains de productivité, selon McKinsey	RE

Autres langues

29/06	Gedeon Richter plc announces Resignation of Péter Cserháti as Member of the Board of Directors, with Effect from 1 July 2026
16/06	AI in Hungary could unlock productivity gains of EUR15 billion, McKinsey says
10/06	Gedeon Richter : Richter and Hetero Announce Global Cooperation for the Development and Commercialization of Semaglutide Injection (Generic of Ozempic®)
10/06	Gedeon Richter Plc. and Hetero Labs Ltd. Announce Global Collaboration Agreement for Joint Development, Registration, and Commercialization of Semaglutide Injection
29/05	Gedeon Richter PLC Approves Dividend for the Financial Year 2025
27/05	Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia
27/05	Gedeon Richter : Richter and Acrux agree to license Lenzetto® for Australia
14/05	Gedeon Richter : Transactions with Treasury Shares
12/05	Gedeon Richter PLC Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05	Gedeon Richter : Extraordinary Information
12/05	Hungary's Richter says 2026 guidance fully reiterated high-single-digit growth in revenues and clean EBIT (at constant exchange rates)
12/05	Gedeon Richter : Interim management statement
12/05	Gedeon Richter : RichterIRpresentation May 2026
12/05	Gedeon Richter : PresentationQ12026
12/05	Gedeon Richter : Richter publishes Q1 2026 results
12/05	Gedeon Richter : Earnings presentation Q1 2026 (PresentationQ12026)
12/05	Gedeon Richter : Investor presentation Q1 2026 (RichterIRpresentation May 2026)
12/05	Gedeon Richter Seeks Acquisitions
29/04	Gedeon Richter : Corporate Governance Report from 2025
29/04	Gedeon Richter : AGM Resolutions
29/04	Gedeon Richter : Remuneration Report
29/04	Gedeon Richter : CG Declaration
29/04	Gedeon Richter : GM - Resolutions
29/04	Gedeon Richter : Update on Phase II study of ABBV-932 (RGH-932) for the treatment of bipolar depression
29/04	Gedeon Richter Provides Update On Phase II Clinical Trial Of ABBV-932 (RGH-932) For Bipolar Depression